Go offline with the Player FM app!
How GLP-1 Agonists Are Changing Obesity Care with Dr. Spencer Nadolsky
Manage episode 376833018 series 2955924
GLP-1 agonist medications have been a popular topic of discussion recently. While this weight loss drug was designed for obesity, GLP-1 agonists like Ozempic have made their way into Hollywood. This has people questioning their safety and possible health risks, especially in the long run. Are GLP-1 agonists a quick fix for weight loss or a lifetime prescription? Who should be prescribed this medication, and what are the possible side effects?
This Longevity by Design episode features an interview with Dr. Spencer Nadolsky—An obesity and lipid specialist physician. Dr. Nadolsky explains how GLP-1 medications cause weight loss, answers questions about safety concerns, and discusses interesting patient stories about how people react to this medication. Dr. Nadolsky has a lot of patient experience with GLP-1 agonist drugs and is very knowledgeable about their current use and future potential.
Timestamps:
- Introduction: (0:00–2:00)
- Why Dr. Nadolsky became a physician: (2:00–4:13)
- What is cardiometabolic medicine?: (4:13–5:17)
- What is a “healthy” metabolism?: (5:17–7:37)
- How does diet impact glucose regulation: (7:37–10:20)
- Why has insulin resistance increased in the past decade?: (10:20–11:45)
- Ethnicity impacts BMI cutoffs: (11:45–12:57)
- Is obesity a choice?: (12:57–17:40)
- How socioeconomic status impacts obesity: (17:40–21:30)
- What's better: A BMI score or a DEXA scan?: (21:30–25:33)
- How strength training improves healthspan: (25:33–32:32)
- What a fasting insulin blood test tells you: (32:32–36:58)
- Health risks of insulin resistance: (35:15–38:08)
- How insulin resistance can increase ApoB: (38:08–39:25)
- How does ApoB predict heart disease risk?: (39:25–42:50)
- Why isn't ApoB included in typical lipid panels?: (42:50–44:25)
- Behavioral science and clinical practice: (44:25–50:06)
- How do GLP-1 agonists cause weight loss? (50:06–56:03)
- Negative side effects of GLP-1 medications: (56:03–57:36)
- Price of GLP-1s: (57:36–58:53)
- GLP-1: A short term quick fix or a lifetime prescription?: (58:53–1:02:19)
- Biggest health myths on social media: (1:02:19–1:08:45)
- Top tip for healthspan: (1:08:45–end)
Longevity By Design is produced by InsideTracker. InsideTracker provides a personalized health analysis and data-driven wellness guide to help you add years to your life—and life to your years. Choose a plan that best fits your needs to get your comprehensive biomarker analysis, customized action plan, and customer-exclusive healthspan resources.
Listen to all episodes of Longevity By Design at https://info.insidetracker.com/longevitybydesign
67 episodes
Manage episode 376833018 series 2955924
GLP-1 agonist medications have been a popular topic of discussion recently. While this weight loss drug was designed for obesity, GLP-1 agonists like Ozempic have made their way into Hollywood. This has people questioning their safety and possible health risks, especially in the long run. Are GLP-1 agonists a quick fix for weight loss or a lifetime prescription? Who should be prescribed this medication, and what are the possible side effects?
This Longevity by Design episode features an interview with Dr. Spencer Nadolsky—An obesity and lipid specialist physician. Dr. Nadolsky explains how GLP-1 medications cause weight loss, answers questions about safety concerns, and discusses interesting patient stories about how people react to this medication. Dr. Nadolsky has a lot of patient experience with GLP-1 agonist drugs and is very knowledgeable about their current use and future potential.
Timestamps:
- Introduction: (0:00–2:00)
- Why Dr. Nadolsky became a physician: (2:00–4:13)
- What is cardiometabolic medicine?: (4:13–5:17)
- What is a “healthy” metabolism?: (5:17–7:37)
- How does diet impact glucose regulation: (7:37–10:20)
- Why has insulin resistance increased in the past decade?: (10:20–11:45)
- Ethnicity impacts BMI cutoffs: (11:45–12:57)
- Is obesity a choice?: (12:57–17:40)
- How socioeconomic status impacts obesity: (17:40–21:30)
- What's better: A BMI score or a DEXA scan?: (21:30–25:33)
- How strength training improves healthspan: (25:33–32:32)
- What a fasting insulin blood test tells you: (32:32–36:58)
- Health risks of insulin resistance: (35:15–38:08)
- How insulin resistance can increase ApoB: (38:08–39:25)
- How does ApoB predict heart disease risk?: (39:25–42:50)
- Why isn't ApoB included in typical lipid panels?: (42:50–44:25)
- Behavioral science and clinical practice: (44:25–50:06)
- How do GLP-1 agonists cause weight loss? (50:06–56:03)
- Negative side effects of GLP-1 medications: (56:03–57:36)
- Price of GLP-1s: (57:36–58:53)
- GLP-1: A short term quick fix or a lifetime prescription?: (58:53–1:02:19)
- Biggest health myths on social media: (1:02:19–1:08:45)
- Top tip for healthspan: (1:08:45–end)
Longevity By Design is produced by InsideTracker. InsideTracker provides a personalized health analysis and data-driven wellness guide to help you add years to your life—and life to your years. Choose a plan that best fits your needs to get your comprehensive biomarker analysis, customized action plan, and customer-exclusive healthspan resources.
Listen to all episodes of Longevity By Design at https://info.insidetracker.com/longevitybydesign
67 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.